MTOR and thyroid gland carcinoma: IMCA may be a specific antagonist of NR4A1 through the nuclear export of NR4A1 and the p53-sestrins-AMPK-mTOR signaling pathway, meaning it may be a promising drug candidate to treat thyroid carcinomas.